NCT06382402

Brief Summary

This study design is a prospective randomized control trial to compare outcomes between the utilization of coronary computed tomography angiography (CCTA) vs conservative treatment in type 2 NSTEMI. The targeted population is expectedly heterogeneous and inpatient setting who are admitted and diagnosed with type 2 NSTEMI.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started May 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 19, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 24, 2024

Completed
7 days until next milestone

Study Start

First participant enrolled

May 1, 2024

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2025

Completed
Last Updated

March 17, 2025

Status Verified

May 1, 2024

Enrollment Period

8 months

First QC Date

April 19, 2024

Last Update Submit

March 13, 2025

Conditions

Outcome Measures

Primary Outcomes (6)

  • MACE

    Time to the first major adverse cardiac event (MACE) at 3 years between 2 groups. Unit: no unit (yes/no)

    anytime within 3 years

  • Cardiovascular (CV) mortality

    Cardiovascular (CV) mortality Unit: no unit (yes/no)

    anytime within 3 years

  • Nonfatal MI, stroke

    Nonfatal MI, stroke Unit: no unit (yes or no)

    anytime within 3 years

  • Hospitalization for unstable angina

    Hospitalization for unstable angina Unit: no unit (yes or no)

    anytime within 3 years

  • Hospitalization for heart failure

    Hospitalization for heart failure Unit: no unit (yes or no)

    anytime within 3 years

  • Unplanned revascularization

    Unplanned revascularization Unit: no unit (yes or no)

    anytime within 3 years

Secondary Outcomes (5)

  • All-cause mortality

    anytime within 3 years

  • In-hospital and 90-day costs

    anytime within 90 days

  • Patient quality of life at 90 days

    anytime within 90 days

  • Diagnostic certainty scores

    anytime within 3 years

  • Individual components of the primary endpoint

    anytime within 3 years

Study Arms (2)

CCTA Group

CT group will undergo CCTA to evaluate for coronary artery disease to early address underlying CAD and then care will be directed based on the findings of that CT scan.

Radiation: CCTA scan

No CCTA Group

Group 2 will not undergo CCTA and will be managed at the discretion of the primary team using the standard of care pathway comprising of either conservative medical management, stress testing, or invasive evaluation with coronary angiography in the catheterization laboratory.

Interventions

CCTA scanRADIATION

• CCTA will be performed per the standard clinical protocol using a Cannon Aquilion ONE scanner with 16 cm z-axis coverage at 0.5 mm resolution, low contrast, and reduced radiation dose requirements.

CCTA Group

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Hospitalized patients diagnosed with type 2 NSTEMI.

You may qualify if:

  • Inpatient with type 2 NSTEMI
  • Aged 18-70 years old
  • At the University of Louisville and Jewish hospitals

You may not qualify if:

  • History of severe or anaphylactic reaction to iodinated contrast
  • Inability to cooperate with scan protocols
  • Hemodynamic instability
  • Decompensated heart failure
  • Acute myocardial infarction
  • Renal impairment with GFR \< 30
  • Pregnancy
  • Inability to tolerate heart rate-slowing medications or nitroglycerin
  • Recent phosphodiesterase inhibitor use
  • Severe aortic stenosis
  • Bronchospastic disease
  • Patient's weight and height

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Louisville School of Medicine, Division of Cardiovascular Diseases

Louisville, Kentucky, 40202, United States

Location

Study Officials

  • Dinesh Kalra, MD

    University of Louisville School of Medicine

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 19, 2024

First Posted

April 24, 2024

Study Start

May 1, 2024

Primary Completion

January 1, 2025

Study Completion

January 1, 2025

Last Updated

March 17, 2025

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations